{
    "info": {
        "nct_id": "NCT03175432",
        "official_title": "Phase II Study of BEvacizumab (Avastin) in Combination With Atezolizumab or Atezolizumab (Tencentriq) and Cobimetinib (Cotellic) in Patients With Untreated Melanoma Brain Metastases (TACo-BEAT-MBM)",
        "inclusion_criteria": "* Signed informed consent form (ICF)\n* Age >/= 18 years\n* Ability and willingness to comply with the requirements of the study protocol\n* Life expectancy > 12 weeks\n* Asymptomatic off steroids for at least 10 days except patients: a) who have mild symptoms from intracranial disease that do not affect their performance status; or b) who are asymptomatic, but require steroids for control of symptoms on a maximum dose of dexamethasone 4mg/day orally (PO) or equivalent\n* Prior therapies for extracranial metastatic melanoma including chemotherapy, BRAFi/MEKi, cytokine or vaccine therapy as long as it did not include PD-1/PD-L1. Note: Patients who are PD-1 refractory are allowed to enroll into the TACo arm if BRAFV600 wild-type is confirmed. Patients that are known to have BRAFV600 mutation must have received prior BRAFi/MEKi prior to enrolling on TACo. Patients that have received prior BRAF/MEKi have to have received their last dose of BRAF/MEKi > 3 months prior to being treated on this study.\n* At least one measurable intracranial target lesion for which all of the following criteria are met: a) Previously untreated or progressive after previous local therapy b) Immediate local therapy clinically not indicated or patient is not a suitable candidate to receive immediate local therapy c) Largest diameter of >= 0.5 cm, but =< 3 cm as determined by contrast-enhanced MRI\n* Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks (blocks are preferred) or at least 4 unstained slides, with an associated pathology report, for central testing of tumor PD-L1 expression a) Tumor tissue should be of good quality based on total and viable tumor content. Fine needle aspiration, brushing, cell pellet from pleural effusion, bone metastases, and lavage samples are not acceptable. For core-needle biopsy specimens, at least three cores should be submitted for evaluation. b) Patients who do not have tissue specimens meeting eligibility requirements may undergo a biopsy during the screening period. Acceptable samples include core needle biopsies for deep tumor tissue (minimum of three cores) or excisional, incisional, punch, or forceps biopsies for cutaneous, subcutaneous, or mucosal lesions. c) Tumor tissue from bone metastases is not evaluable for PD-L1 expression and is therefore not acceptable\n* Histologically or cytologically confirmed BRAFV600 wild-type melanoma through archival or newly obtained tissue.(only patients who are PD-1 refractory who will enroll onto the TACo arm)\n* Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Absolute neutrophil count (ANC) >= 1500 cells/u\n* Obtained within 14 days prior to the first study treatment (cycle 1, day 1): White blood cell (WBC) counts > 2500/uL\n* Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Lymphocyte count >= 500/uL\n* Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Platelet count >= 100,000/uL\n* Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Hemoglobin >= 9.0 g/dL\n* Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Total bilirubin =< 1.5 x upper limit of normal (ULN) with the following exception: 1) patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may be enrolled\n* Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN with the following exception: 1) patients with documented liver metastases: AST and/or ALT =< 5 x ULN\n* Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Alkaline phosphatase =< 2.5 x ULN with the following exception: 1) =< 5 x ULN in patients with documented liver metastases =< 7 x ULN in patients with documented bone metastases\n* Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Serum creatinine =< 1.5 x ULN or creatinine clearance >= 50 mL/min on the basis of the Cockcroft-Gault glomerular filtration rate estimation\n* Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Urine dipstick for proteinuria < 2+ unless a 24-hour urine protein =< 1 g of protein is demonstrated\n* For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for at least 12 months after the last dose of atezolizumab\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n* International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN within 7 days prior to study enrollment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Symptomatic brain metastases requiring immediate local interventions such as craniotomy or stereotactic radiosurgery (SRS)\n* Patients who require immediate surgical or radiotherapy interventions\n* Increasing corticosteroid dose in 7 days prior to administration of first dose of study drug. Symptomatic patients who have stable or decreasing corticosteroid use in the past 7 days may be included\n* Patients with leptomeningeal disease\n* Any approved anticancer therapy, including chemotherapy and hormonal therapy within 3 weeks prior to initiation of study treatment; however, the following are allowed: a) Hormone-replacement therapy or oral contraceptives b) Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)\n* Current, recent (within 3 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study\n* Adverse events (AEs) from prior anticancer therapy that have not resolved to grade =< 1 except for alopecia\n* Bisphosphonate therapy for symptomatic hypercalcemia a) Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed\n* Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease. Patients with acute leukemias, accelerated/blast phase chronic myelogenous leukemia, chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or non-secretory myeloma\n* Patients who are pregnant, lactating, or breastfeeding\n* Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies\n* Inability to undergo MRI secondary to: a) metal b) claustrophobia c) gadolinium contrast allergy\n* Prior radiation therapy within the last 14 days\n* Inability to comply with study and follow-up procedures\n* History of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis a) Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible. b) Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible. c) Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations; rash must cover less than 10% of body surface area (BSA)\n* Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%) No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)\n* History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan a) history of radiation pneumonitis in the radiation field (fibrosis) is permitted\n* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications\n* History of human immunodeficiency virus (HIV) infection or active hepatitis B (chronic or acute) or hepatitis C infection; a) Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible; b) Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)\n* Active tuberculosis\n* Severe infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia\n* Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1\n* Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study a) Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study\n* Malignancies other than the disease under study within 5 years prior to cycle 1, day 1, with the exception of those with a negligible risk of metastasis or death and with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, or ductal carcinoma in situ treated surgically with curative intent) or undergoing active surveillance per standard-of-care management (e.g., chronic lymphocytic leukemia Rai Stage 0, prostate cancer with Gleason score =< 6, and prostate-specific antigen [PSA] =< 10 mg/mL, etc.)\n* Known hypersensitivity to any component of bevacizumab, atezolizumab, or cobimetinib\n* Life expectancy of less than 12 weeks\n* (Atezolizumab-related exclusion) Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents a) Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met: Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose. No history of severe immune-related adverse effects from anti-CTLA 4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] Grade 3 and 4) Patients who are PD-1 refractory are allowed to enroll into the TACo arm regardless of BRAF status.\n* (Atezolizumab-related exclusion) Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]-(alpha) or interleukin [IL]-2) within 6 weeks or five half-lives of the drug (whichever is shorter) prior to cycle 1, day 1\n* (Atezolizumab-related exclusion) Treatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half lives of the investigational product, whichever is longer)\n* (Atezolizumab-Related Exclusion) Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1 a) Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled. b) The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed\n* (Atezolizumab-related exclusion) History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins\n* (Atezolizumab-related exclusion) Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation\n* (Bevacizumab-related exclusion) Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg)\n* (Bevacizumab-related exclusion) Prior history of hypertensive crisis or hypertensive encephalopathy\n* (Bevacizumab-related exclusion) Clinically significant (i.e. active) cardiovascular disease, for example cerebrovascular accidents =< 6 months prior to study enrolment, myocardial infarction =< 6 months prior to study enrollment, unstable angina, grade II or greater congestive heart failure, or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment\n* (Bevacizumab-related exclusion) History or evidence upon physical/neurological examination of central nervous system (CNS) disease (e.g. seizures) unrelated to cancer unless adequately treated with standard medical therapy\n* (Bevacizumab-related exclusion) Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior of study enrollment\n* (Bevacizumab-related exclusion) Any previous venous thromboembolism > NCI CTCAE grade 3\n* (Bevacizumab-related exclusion) History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month of study enrollment for any tumor type\n* (Bevacizumab-related exclusion) Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)\n* (Bevacizumab-related exclusion) Current or recent (within 10 days of study enrolment) use of aspirin (> 325 mg/day), clopidogrel (> 75 mg/day), or current or recent (within 10 days prior to first dose of bevacizumab) use of therapeutic oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes Note: The use of full-dose oral or parenteral anticoagulants is NOT permitted for at least two weeks at the time of study enrollment. Prophylactic use of anticoagulants is NOT allowed\n* (Bevacizumab-related exclusion) Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to study enrollment, or anticipation of need for major surgical procedure during the course of the study. For patients with brain tumours, craniotomy or intracranial biopsy sites must be adequately healed; free of drainage or cellulitis, and the underlying cranioplasty must appear intact at the time of study enrolment.\n\n  * History of abdominal fistula or gastrointestinal perforation within 6 months prior to to the first study treatment Serious, non-healing wound, active ulcer, or untreated bone fracture (Adjuvant trials: bone fractures must be healed)\n  * Proteinuria as demonstrated by a UPC ratio >= 1.0 at screening\n\nCobimetinib-Related Exclusion Criteria:\n\n* Inability to swallow medications\n* Malabsorption condition that would alter the absorption of rally administered medications\n* Ocular Melanoma\n* Left Ventricular Ejection Fraction (LVEF) is below the institutional lower limit of normal or <50%, whichever is lower.\n* History or presence of an abnormal electrocardiogram (ECG) that is clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third-degree heart block, or evidence of prior myocardial infarction.\n* Patients who meet any of the following exclusion criteria related to ocular disease will be excluded from study entry:\n\n  * Known risk factors for ocular toxicity, consisting of any of the following:\n  * History of serous retinopathy\n  * History of retinal vein occlusion (RVO)\n  * Evidence of ongoing serous retinopathy or RVO at screening",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Signed informed consent form (ICF)",
            "criterions": [
                {
                    "exact_snippets": "Signed informed consent form (ICF)",
                    "criterion": "informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age >/= 18 years",
            "criterions": [
                {
                    "exact_snippets": "Age >/= 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability and willingness to comply with the requirements of the study protocol",
            "criterions": [
                {
                    "exact_snippets": "Ability and willingness to comply with the requirements of the study protocol",
                    "criterion": "compliance with study protocol",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy > 12 weeks",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy > 12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Asymptomatic off steroids for at least 10 days except patients: a) who have mild symptoms from intracranial disease that do not affect their performance status; or b) who are asymptomatic, but require steroids for control of symptoms on a maximum dose of dexamethasone 4mg/day orally (PO) or equivalent",
            "criterions": [
                {
                    "exact_snippets": "Asymptomatic",
                    "criterion": "symptom status",
                    "requirements": [
                        {
                            "requirement_type": "asymptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "off steroids for at least 10 days",
                    "criterion": "steroid use",
                    "requirements": [
                        {
                            "requirement_type": "duration off steroids",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "mild symptoms from intracranial disease that do not affect their performance status",
                    "criterion": "intracranial disease symptoms",
                    "requirements": [
                        {
                            "requirement_type": "symptom severity",
                            "expected_value": "mild"
                        },
                        {
                            "requirement_type": "impact on performance status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "asymptomatic, but require steroids for control of symptoms on a maximum dose of dexamethasone 4mg/day orally (PO) or equivalent",
                    "criterion": "steroid use for symptom control",
                    "requirements": [
                        {
                            "requirement_type": "asymptomatic",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "steroid dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "mg/day dexamethasone or equivalent"
                            }
                        },
                        {
                            "requirement_type": "route of administration",
                            "expected_value": "orally (PO)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior therapies for extracranial metastatic melanoma including chemotherapy, BRAFi/MEKi, cytokine or vaccine therapy as long as it did not include PD-1/PD-L1. Note: Patients who are PD-1 refractory are allowed to enroll into the TACo arm if BRAFV600 wild-type is confirmed. Patients that are known to have BRAFV600 mutation must have received prior BRAFi/MEKi prior to enrolling on TACo. Patients that have received prior BRAF/MEKi have to have received their last dose of BRAF/MEKi > 3 months prior to being treated on this study.",
            "criterions": [
                {
                    "exact_snippets": "Prior therapies for extracranial metastatic melanoma including chemotherapy, BRAFi/MEKi, cytokine or vaccine therapy as long as it did not include PD-1/PD-L1.",
                    "criterion": "prior therapies for extracranial metastatic melanoma",
                    "requirements": [
                        {
                            "requirement_type": "types of prior therapy",
                            "expected_value": [
                                "chemotherapy",
                                "BRAFi/MEKi",
                                "cytokine therapy",
                                "vaccine therapy"
                            ]
                        },
                        {
                            "requirement_type": "exclusion of prior therapy",
                            "expected_value": "PD-1/PD-L1"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who are PD-1 refractory are allowed to enroll into the TACo arm if BRAFV600 wild-type is confirmed.",
                    "criterion": "PD-1 refractory status and BRAFV600 wild-type",
                    "requirements": [
                        {
                            "requirement_type": "PD-1 refractory",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "BRAFV600 wild-type",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients that are known to have BRAFV600 mutation must have received prior BRAFi/MEKi prior to enrolling on TACo.",
                    "criterion": "BRAFV600 mutation and prior BRAFi/MEKi therapy",
                    "requirements": [
                        {
                            "requirement_type": "BRAFV600 mutation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior BRAFi/MEKi therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients that have received prior BRAF/MEKi have to have received their last dose of BRAF/MEKi > 3 months prior to being treated on this study.",
                    "criterion": "interval since last BRAFi/MEKi dose",
                    "requirements": [
                        {
                            "requirement_type": "time since last BRAFi/MEKi dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least one measurable intracranial target lesion for which all of the following criteria are met: a) Previously untreated or progressive after previous local therapy b) Immediate local therapy clinically not indicated or patient is not a suitable candidate to receive immediate local therapy c) Largest diameter of >= 0.5 cm, but =< 3 cm as determined by contrast-enhanced MRI",
            "criterions": [
                {
                    "exact_snippets": "At least one measurable intracranial target lesion",
                    "criterion": "intracranial target lesion",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Previously untreated or progressive after previous local therapy",
                    "criterion": "intracranial target lesion prior treatment status",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": [
                                "previously untreated",
                                "progressive after previous local therapy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Immediate local therapy clinically not indicated or patient is not a suitable candidate to receive immediate local therapy",
                    "criterion": "suitability for immediate local therapy",
                    "requirements": [
                        {
                            "requirement_type": "suitability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Largest diameter of >= 0.5 cm, but =< 3 cm as determined by contrast-enhanced MRI",
                    "criterion": "intracranial target lesion size",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0.5,
                                        "unit": "cm"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "cm"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed BRAFV600 wild-type melanoma through archival or newly obtained tissue.(only patients who are PD-1 refractory who will enroll onto the TACo arm)",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed BRAFV600 wild-type melanoma",
                    "criterion": "melanoma",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "BRAFV600 mutation status",
                            "expected_value": "wild-type"
                        }
                    ]
                },
                {
                    "exact_snippets": "through archival or newly obtained tissue",
                    "criterion": "tumor tissue sample",
                    "requirements": [
                        {
                            "requirement_type": "source",
                            "expected_value": [
                                "archival",
                                "newly obtained"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "only patients who are PD-1 refractory who will enroll onto the TACo arm",
                    "criterion": "PD-1 refractory status",
                    "requirements": [
                        {
                            "requirement_type": "PD-1 refractory",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "TACo arm enrollment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks (blocks are preferred) or at least 4 unstained slides, with an associated pathology report, for central testing of tumor PD-L1 expression a) Tumor tissue should be of good quality based on total and viable tumor content. Fine needle aspiration, brushing, cell pellet from pleural effusion, bone metastases, and lavage samples are not acceptable. For core-needle biopsy specimens, at least three cores should be submitted for evaluation. b) Patients who do not have tissue specimens meeting eligibility requirements may undergo a biopsy during the screening period. Acceptable samples include core needle biopsies for deep tumor tissue (minimum of three cores) or excisional, incisional, punch, or forceps biopsies for cutaneous, subcutaneous, or mucosal lesions. c) Tumor tissue from bone metastases is not evaluable for PD-L1 expression and is therefore not acceptable",
            "criterions": [
                {
                    "exact_snippets": "Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks (blocks are preferred) or at least 4 unstained slides, with an associated pathology report",
                    "criterion": "tumor specimen submission",
                    "requirements": [
                        {
                            "requirement_type": "specimen type",
                            "expected_value": [
                                "FFPE tumor specimens in paraffin blocks",
                                "at least 4 unstained slides"
                            ]
                        },
                        {
                            "requirement_type": "pathology report",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for central testing of tumor PD-L1 expression",
                    "criterion": "tumor PD-L1 expression",
                    "requirements": [
                        {
                            "requirement_type": "central testing",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Tumor tissue should be of good quality based on total and viable tumor content.",
                    "criterion": "tumor tissue quality",
                    "requirements": [
                        {
                            "requirement_type": "quality",
                            "expected_value": "good based on total and viable tumor content"
                        }
                    ]
                },
                {
                    "exact_snippets": "Fine needle aspiration, brushing, cell pellet from pleural effusion, bone metastases, and lavage samples are not acceptable.",
                    "criterion": "tumor specimen source",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "fine needle aspiration",
                                "brushing",
                                "cell pellet from pleural effusion",
                                "bone metastases",
                                "lavage samples"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "For core-needle biopsy specimens, at least three cores should be submitted for evaluation.",
                    "criterion": "core-needle biopsy specimen submission",
                    "requirements": [
                        {
                            "requirement_type": "minimum number of cores",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "cores"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who do not have tissue specimens meeting eligibility requirements may undergo a biopsy during the screening period.",
                    "criterion": "biopsy during screening",
                    "requirements": [
                        {
                            "requirement_type": "permitted if no eligible tissue",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Acceptable samples include core needle biopsies for deep tumor tissue (minimum of three cores) or excisional, incisional, punch, or forceps biopsies for cutaneous, subcutaneous, or mucosal lesions.",
                    "criterion": "acceptable biopsy sample type",
                    "requirements": [
                        {
                            "requirement_type": "sample type",
                            "expected_value": [
                                "core needle biopsies for deep tumor tissue (minimum of three cores)",
                                "excisional biopsies",
                                "incisional biopsies",
                                "punch biopsies",
                                "forceps biopsies for cutaneous, subcutaneous, or mucosal lesions"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Tumor tissue from bone metastases is not evaluable for PD-L1 expression and is therefore not acceptable",
                    "criterion": "tumor tissue from bone metastases",
                    "requirements": [
                        {
                            "requirement_type": "acceptability for PD-L1 testing",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Absolute neutrophil count (ANC) >= 1500 cells/u",
            "criterions": [
                {
                    "exact_snippets": "Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Absolute neutrophil count (ANC) >= 1500 cells/u",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "cells/u"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 14 days prior to the first study treatment (cycle 1, day 1)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Obtained within 14 days prior to the first study treatment (cycle 1, day 1): White blood cell (WBC) counts > 2500/uL",
            "criterions": [
                {
                    "exact_snippets": "White blood cell (WBC) counts > 2500/uL",
                    "criterion": "white blood cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2500,
                                "unit": "uL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Lymphocyte count >= 500/uL",
            "criterions": [
                {
                    "exact_snippets": "Lymphocyte count >= 500/uL",
                    "criterion": "lymphocyte count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 500,
                                "unit": "/uL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Platelet count >= 100,000/uL",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >= 100,000/uL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "uL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Hemoglobin >= 9.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 9.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Total bilirubin =< 1.5 x upper limit of normal (ULN) with the following exception: 1) patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may be enrolled",
            "criterions": [
                {
                    "exact_snippets": "Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Total bilirubin =< 1.5 x upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 14 days prior to the first study treatment (cycle 1, day 1)"
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may be enrolled",
                    "criterion": "serum bilirubin (in patients with known Gilbert disease)",
                    "requirements": [
                        {
                            "requirement_type": "condition",
                            "expected_value": "known Gilbert disease"
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN with the following exception: 1) patients with documented liver metastases: AST and/or ALT =< 5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Aspartate aminotransferase (AST) ... =< 2.5 x ULN",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "obtained within 14 days prior to the first study treatment (cycle 1, day 1)"
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Obtained within 14 days prior to the first study treatment (cycle 1, day 1): ... alanine aminotransferase (ALT) =< 2.5 x ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "obtained within 14 days prior to the first study treatment (cycle 1, day 1)"
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with documented liver metastases: AST and/or ALT =< 5 x ULN",
                    "criterion": "AST and/or ALT level in patients with documented liver metastases",
                    "requirements": [
                        {
                            "requirement_type": "condition",
                            "expected_value": "documented liver metastases"
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Alkaline phosphatase =< 2.5 x ULN with the following exception: 1) =< 5 x ULN in patients with documented liver metastases =< 7 x ULN in patients with documented bone metastases",
            "criterions": [
                {
                    "exact_snippets": "Alkaline phosphatase =< 2.5 x ULN",
                    "criterion": "alkaline phosphatase",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Alkaline phosphatase ... =< 5 x ULN in patients with documented liver metastases",
                    "criterion": "alkaline phosphatase (in patients with documented liver metastases)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Alkaline phosphatase ... =< 7 x ULN in patients with documented bone metastases",
                    "criterion": "alkaline phosphatase (in patients with documented bone metastases)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Serum creatinine =< 1.5 x ULN or creatinine clearance >= 50 mL/min on the basis of the Cockcroft-Gault glomerular filtration rate estimation",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine =< 1.5 x ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "creatinine clearance >= 50 mL/min on the basis of the Cockcroft-Gault glomerular filtration rate estimation",
                    "criterion": "creatinine clearance (Cockcroft-Gault)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Obtained within 14 days prior to the first study treatment (cycle 1, day 1): Urine dipstick for proteinuria < 2+ unless a 24-hour urine protein =< 1 g of protein is demonstrated",
            "criterions": [
                {
                    "exact_snippets": "Urine dipstick for proteinuria < 2+ unless a 24-hour urine protein =< 1 g of protein is demonstrated",
                    "criterion": "proteinuria",
                    "requirements": [
                        {
                            "requirement_type": "urine dipstick result",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "+"
                            }
                        },
                        {
                            "requirement_type": "24-hour urine protein",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "g"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for at least 12 months after the last dose of atezolizumab",
            "criterions": [
                {
                    "exact_snippets": "female patients of childbearing potential",
                    "criterion": "female patient childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "male patients with partners of childbearing potential",
                    "criterion": "male patient partner childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "partner childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly) and to continue its use for at least 12 months after the last dose of atezolizumab",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception effectiveness",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "% per year"
                            }
                        },
                        {
                            "requirement_type": "contraception duration after last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN within 7 days prior to study enrollment",
            "criterions": [
                {
                    "exact_snippets": "International normalized ratio (INR) ... =< 1.5 x ULN within 7 days prior to study enrollment",
                    "criterion": "International normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": "within 7 days prior to study enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "activated partial thromboplastin time (aPTT) ... =< 1.5 x ULN within 7 days prior to study enrollment",
                    "criterion": "activated partial thromboplastin time (aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": "within 7 days prior to study enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patients with leptomeningeal disease",
            "criterions": [
                {
                    "exact_snippets": "Patients with leptomeningeal disease",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior radiation therapy within the last 14 days",
            "criterions": [
                {
                    "exact_snippets": "Prior radiation therapy within the last 14 days",
                    "criterion": "prior radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who are pregnant, lactating, or breastfeeding",
            "criterions": [
                {
                    "exact_snippets": "Patients who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "lactating",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bisphosphonate therapy for symptomatic hypercalcemia a) Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed",
            "criterions": [
                {
                    "exact_snippets": "Bisphosphonate therapy for symptomatic hypercalcemia",
                    "criterion": "bisphosphonate therapy",
                    "requirements": [
                        {
                            "requirement_type": "indication",
                            "expected_value": "symptomatic hypercalcemia"
                        }
                    ]
                },
                {
                    "exact_snippets": "Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed",
                    "criterion": "bisphosphonate therapy",
                    "requirements": [
                        {
                            "requirement_type": "indication",
                            "expected_value": [
                                "bone metastasis",
                                "osteoporosis"
                            ]
                        },
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Increasing corticosteroid dose in 7 days prior to administration of first dose of study drug. Symptomatic patients who have stable or decreasing corticosteroid use in the past 7 days may be included",
            "criterions": [
                {
                    "exact_snippets": "Increasing corticosteroid dose in 7 days prior to administration of first dose of study drug",
                    "criterion": "corticosteroid dose",
                    "requirements": [
                        {
                            "requirement_type": "change in dose over past 7 days",
                            "expected_value": "not increasing"
                        }
                    ]
                },
                {
                    "exact_snippets": "Symptomatic patients who have stable or decreasing corticosteroid use in the past 7 days may be included",
                    "criterion": "corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "change in use over past 7 days",
                            "expected_value": [
                                "stable",
                                "decreasing"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Symptomatic patients",
                    "criterion": "symptomatic status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who require immediate surgical or radiotherapy interventions",
            "criterions": [
                {
                    "exact_snippets": "Patients who require immediate surgical ... interventions",
                    "criterion": "requirement for immediate surgical intervention",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who require immediate ... radiotherapy interventions",
                    "criterion": "requirement for immediate radiotherapy intervention",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy of less than 12 weeks",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of less than 12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (Bevacizumab-related exclusion) Any previous venous thromboembolism > NCI CTCAE grade 3",
            "criterions": [
                {
                    "exact_snippets": "Any previous venous thromboembolism > NCI CTCAE grade 3",
                    "criterion": "previous venous thromboembolism",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "NCI CTCAE grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1",
            "criterions": [
                {
                    "exact_snippets": "Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inability to undergo MRI secondary to: a) metal b) claustrophobia c) gadolinium contrast allergy",
            "criterions": [
                {
                    "exact_snippets": "Inability to undergo MRI",
                    "criterion": "ability to undergo MRI",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "metal",
                    "criterion": "presence of metal in body",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "claustrophobia",
                    "criterion": "claustrophobia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "gadolinium contrast allergy",
                    "criterion": "gadolinium contrast allergy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adverse events (AEs) from prior anticancer therapy that have not resolved to grade =< 1 except for alopecia",
            "criterions": [
                {
                    "exact_snippets": "Adverse events (AEs) from prior anticancer therapy that have not resolved to grade =< 1 except for alopecia",
                    "criterion": "adverse events from prior anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity grade",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for alopecia",
                    "criterion": "alopecia from prior anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "exclusion from severity requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (Atezolizumab-related exclusion) Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation",
            "criterions": [
                {
                    "exact_snippets": "prior allogeneic bone marrow transplantation",
                    "criterion": "allogeneic bone marrow transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior solid organ transplantation",
                    "criterion": "solid organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active tuberculosis",
            "criterions": [
                {
                    "exact_snippets": "Active tuberculosis",
                    "criterion": "tuberculosis",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (Atezolizumab-related exclusion) History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins",
            "criterions": [
                {
                    "exact_snippets": "History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins",
                    "criterion": "hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "reaction_type",
                            "expected_value": [
                                "allergic",
                                "anaphylactic",
                                "other hypersensitivity"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (Bevacizumab-related exclusion) Prior history of hypertensive crisis or hypertensive encephalopathy",
            "criterions": [
                {
                    "exact_snippets": "Prior history of hypertensive crisis",
                    "criterion": "hypertensive crisis",
                    "requirements": [
                        {
                            "requirement_type": "prior history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior history of ... hypertensive encephalopathy",
                    "criterion": "hypertensive encephalopathy",
                    "requirements": [
                        {
                            "requirement_type": "prior history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Proteinuria as demonstrated by a UPC ratio >= 1.0 at screening",
            "criterions": [
                {
                    "exact_snippets": "Proteinuria as demonstrated by a UPC ratio >= 1.0 at screening",
                    "criterion": "UPC ratio",
                    "requirements": [
                        {
                            "requirement_type": "value at screening",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.0,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inability to comply with study and follow-up procedures",
            "criterions": [
                {
                    "exact_snippets": "Inability to comply with study and follow-up procedures",
                    "criterion": "ability to comply with study and follow-up procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current, recent (within 3 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study",
            "criterions": [
                {
                    "exact_snippets": "Current, recent (within 3 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study",
                    "criterion": "participation in an experimental drug study",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "current",
                                "recent (within 3 weeks of the first infusion of this study)",
                                "planned"
                            ]
                        },
                        {
                            "requirement_type": "sponsor exclusion",
                            "expected_value": "other than a Genentech-sponsored bevacizumab cancer study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Symptomatic brain metastases requiring immediate local interventions such as craniotomy or stereotactic radiosurgery (SRS)",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring immediate local interventions such as craniotomy or stereotactic radiosurgery (SRS)",
                    "criterion": "need for immediate local intervention for brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "requirement for immediate local intervention",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "intervention type",
                            "expected_value": [
                                "craniotomy",
                                "stereotactic radiosurgery (SRS)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (Atezolizumab-related exclusion) Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]-(alpha) or interleukin [IL]-2) within 6 weeks or five half-lives of the drug (whichever is shorter) prior to cycle 1, day 1",
            "criterions": [
                {
                    "exact_snippets": "Treatment with systemic immunostimulatory agents (including but not limited to interferon [IFN]-(alpha) or interleukin [IL]-2) within 6 weeks or five half-lives of the drug (whichever is shorter) prior to cycle 1, day 1",
                    "criterion": "treatment with systemic immunostimulatory agents",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (Bevacizumab-related exclusion) Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg)",
            "criterions": [
                {
                    "exact_snippets": "Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg)",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "inadequately controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "systolic blood pressure > 150 mmHg",
                    "criterion": "systolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 150,
                                "unit": "mmHg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "diastolic blood pressure > 100 mmHg",
                    "criterion": "diastolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "mmHg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who meet any of the following exclusion criteria related to ocular disease will be excluded from study entry:",
            "criterions": [
                {
                    "exact_snippets": "exclusion criteria related to ocular disease",
                    "criterion": "ocular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (Atezolizumab-related exclusion) Treatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half lives of the investigational product, whichever is longer)",
            "criterions": [
                {
                    "exact_snippets": "Treatment with investigational agent within 4 weeks prior to cycle 1, day 1 (or within five half lives of the investigational product, whichever is longer)",
                    "criterion": "treatment with investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half lives of the investigational product"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease. Patients with acute leukemias, accelerated/blast phase chronic myelogenous leukemia, chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or non-secretory myeloma",
            "criterions": [
                {
                    "exact_snippets": "Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease.",
                    "criterion": "clinically significant liver disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active viral ... hepatitis",
                    "criterion": "active viral hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "alcoholic ... hepatitis",
                    "criterion": "alcoholic hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other hepatitis",
                    "criterion": "other hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cirrhosis",
                    "criterion": "cirrhosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "fatty liver",
                    "criterion": "fatty liver",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "inherited liver disease",
                    "criterion": "inherited liver disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with acute leukemias",
                    "criterion": "acute leukemias",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "accelerated/blast phase chronic myelogenous leukemia",
                    "criterion": "accelerated/blast phase chronic myelogenous leukemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic lymphocytic leukemia",
                    "criterion": "chronic lymphocytic leukemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Burkitt lymphoma",
                    "criterion": "Burkitt lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "plasma cell leukemia",
                    "criterion": "plasma cell leukemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "non-secretory myeloma",
                    "criterion": "non-secretory myeloma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to Chinese hamster ovary cell products",
                    "criterion": "hypersensitivity to Chinese hamster ovary cell products",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity to ... other recombinant human antibodies",
                    "criterion": "hypersensitivity to recombinant human antibodies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known risk factors for ocular toxicity, consisting of any of the following:",
            "criterions": [
                {
                    "exact_snippets": "Known risk factors for ocular toxicity",
                    "criterion": "risk factors for ocular toxicity",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of retinal vein occlusion (RVO)",
            "criterions": [
                {
                    "exact_snippets": "History of retinal vein occlusion (RVO)",
                    "criterion": "retinal vein occlusion (RVO)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications",
            "criterions": [
                {
                    "exact_snippets": "Any other diseases ... giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug",
                    "criterion": "other diseases or conditions",
                    "requirements": [
                        {
                            "requirement_type": "contraindication to investigational drug",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding ... that may affect the interpretation of the results",
                    "criterion": "diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding",
                    "requirements": [
                        {
                            "requirement_type": "may affect interpretation of results",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding ... render the patient at high risk from treatment complications",
                    "criterion": "diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding",
                    "requirements": [
                        {
                            "requirement_type": "high risk from treatment complications",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of human immunodeficiency virus (HIV) infection or active hepatitis B (chronic or acute) or hepatitis C infection; a) Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible; b) Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)",
            "criterions": [
                {
                    "exact_snippets": "History of human immunodeficiency virus (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis B (chronic or acute)",
                    "criterion": "active hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis C infection",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible",
                    "criterion": "past or resolved hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "HBsAg test",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "anti-HBc antibody test",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)",
                    "criterion": "hepatitis C virus (HCV) antibody positivity with negative HCV RNA PCR",
                    "requirements": [
                        {
                            "requirement_type": "HCV antibody",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "HCV RNA PCR",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Cobimetinib-Related Exclusion Criteria:",
            "criterions": [
                {
                    "exact_snippets": "Cobimetinib-Related Exclusion Criteria",
                    "criterion": "cobimetinib-related exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "See protocol for specific cobimetinib-related exclusion criteria; this line is a heading and does not specify atomic criteria."
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of serous retinopathy",
            "criterions": [
                {
                    "exact_snippets": "History of serous retinopathy",
                    "criterion": "serous retinopathy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (Bevacizumab-related exclusion) History or evidence upon physical/neurological examination of central nervous system (CNS) disease (e.g. seizures) unrelated to cancer unless adequately treated with standard medical therapy",
            "criterions": [
                {
                    "exact_snippets": "History or evidence upon physical/neurological examination of central nervous system (CNS) disease (e.g. seizures) unrelated to cancer unless adequately treated with standard medical therapy",
                    "criterion": "central nervous system (CNS) disease unrelated to cancer",
                    "requirements": [
                        {
                            "requirement_type": "history or evidence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated with standard medical therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Left Ventricular Ejection Fraction (LVEF) is below the institutional lower limit of normal or <50%, whichever is lower.",
            "criterions": [
                {
                    "exact_snippets": "Left Ventricular Ejection Fraction (LVEF) is below the institutional lower limit of normal or <50%, whichever is lower.",
                    "criterion": "Left Ventricular Ejection Fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 50,
                                        "unit": "%"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (Bevacizumab-related exclusion) Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior of study enrollment",
            "criterions": [
                {
                    "exact_snippets": "Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior of study enrollment",
                    "criterion": "significant vascular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to study enrollment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aortic aneurysm",
                    "criterion": "aortic aneurysm",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring surgical repair",
                    "criterion": "vascular disease requiring surgical repair",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "surgical repair"
                        }
                    ]
                },
                {
                    "exact_snippets": "recent peripheral arterial thrombosis",
                    "criterion": "peripheral arterial thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": "recent"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Malignancies other than the disease under study within 5 years prior to cycle 1, day 1, with the exception of those with a negligible risk of metastasis or death and with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, or ductal carcinoma in situ treated surgically with curative intent) or undergoing active surveillance per standard-of-care management (e.g., chronic lymphocytic leukemia Rai Stage 0, prostate cancer with Gleason score =< 6, and prostate-specific antigen [PSA] =< 10 mg/mL, etc.)",
            "criterions": [
                {
                    "exact_snippets": "Malignancies other than the disease under study within 5 years prior to cycle 1, day 1",
                    "criterion": "history of other malignancies",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "disease type",
                            "expected_value": "malignancy other than the disease under study"
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of those with a negligible risk of metastasis or death and with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, or ductal carcinoma in situ treated surgically with curative intent)",
                    "criterion": "prior malignancy risk and outcome",
                    "requirements": [
                        {
                            "requirement_type": "risk of metastasis or death",
                            "expected_value": "negligible"
                        },
                        {
                            "requirement_type": "expected outcome",
                            "expected_value": "curative"
                        }
                    ]
                },
                {
                    "exact_snippets": "undergoing active surveillance per standard-of-care management (e.g., chronic lymphocytic leukemia Rai Stage 0, prostate cancer with Gleason score =< 6, and prostate-specific antigen [PSA] =< 10 mg/mL, etc.)",
                    "criterion": "active surveillance for specific cancers",
                    "requirements": [
                        {
                            "requirement_type": "management",
                            "expected_value": "active surveillance"
                        },
                        {
                            "requirement_type": "disease type",
                            "expected_value": [
                                "chronic lymphocytic leukemia Rai Stage 0",
                                "prostate cancer with Gleason score =< 6 and PSA =< 10 mg/mL"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (Bevacizumab-related exclusion) Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to study enrollment, or anticipation of need for major surgical procedure during the course of the study. For patients with brain tumours, craniotomy or intracranial biopsy sites must be adequately healed; free of drainage or cellulitis, and the underlying cranioplasty must appear intact at the time of study enrolment.",
            "criterions": [
                {
                    "exact_snippets": "Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to study enrollment",
                    "criterion": "recent major surgery or significant traumatic injury",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation of need for major surgical procedure during the course of the study",
                    "criterion": "anticipated need for major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "anticipated need during study",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "For patients with brain tumours, craniotomy or intracranial biopsy sites must be adequately healed",
                    "criterion": "healing status of craniotomy or intracranial biopsy sites (in brain tumour patients)",
                    "requirements": [
                        {
                            "requirement_type": "adequate healing",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "free of drainage or cellulitis",
                    "criterion": "craniotomy or intracranial biopsy sites (in brain tumour patients)",
                    "requirements": [
                        {
                            "requirement_type": "drainage",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "cellulitis",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "the underlying cranioplasty must appear intact at the time of study enrolment",
                    "criterion": "cranioplasty integrity (in brain tumour patients)",
                    "requirements": [
                        {
                            "requirement_type": "integrity",
                            "expected_value": "intact"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History or presence of an abnormal electrocardiogram (ECG) that is clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third-degree heart block, or evidence of prior myocardial infarction.",
            "criterions": [
                {
                    "exact_snippets": "History or presence of an abnormal electrocardiogram (ECG) that is clinically significant in the investigator's opinion",
                    "criterion": "abnormal electrocardiogram (ECG)",
                    "requirements": [
                        {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance (investigator's opinion)",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "including complete left bundle branch block",
                    "criterion": "complete left bundle branch block",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "second- or third-degree heart block",
                    "criterion": "second-degree heart block",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "second- or third-degree heart block",
                    "criterion": "third-degree heart block",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of prior myocardial infarction",
                    "criterion": "prior myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "evidence of history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of abdominal fistula or gastrointestinal perforation within 6 months prior to to the first study treatment Serious, non-healing wound, active ulcer, or untreated bone fracture (Adjuvant trials: bone fractures must be healed)",
            "criterions": [
                {
                    "exact_snippets": "History of abdominal fistula or gastrointestinal perforation within 6 months prior to to the first study treatment",
                    "criterion": "abdominal fistula",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of abdominal fistula or gastrointestinal perforation within 6 months prior to to the first study treatment",
                    "criterion": "gastrointestinal perforation",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Serious, non-healing wound",
                    "criterion": "wound",
                    "requirements": [
                        {
                            "requirement_type": "healing_status",
                            "expected_value": "serious, non-healing"
                        }
                    ]
                },
                {
                    "exact_snippets": "active ulcer",
                    "criterion": "ulcer",
                    "requirements": [
                        {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "untreated bone fracture (Adjuvant trials: bone fractures must be healed)",
                    "criterion": "bone fracture",
                    "requirements": [
                        {
                            "requirement_type": "treatment_status",
                            "expected_value": "untreated"
                        },
                        {
                            "requirement_type": "healing_status",
                            "expected_value": "must be healed (for adjuvant trials)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ocular Melanoma",
            "criterions": [
                {
                    "exact_snippets": "Ocular Melanoma",
                    "criterion": "ocular melanoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (Atezolizumab-Related Exclusion) Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1 a) Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled. b) The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed",
            "criterions": [
                {
                    "exact_snippets": "Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1",
                    "criterion": "systemic immunosuppressive medication use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (Atezolizumab-related exclusion) Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents a) Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met: Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose. No history of severe immune-related adverse effects from anti-CTLA 4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] Grade 3 and 4) Patients who are PD-1 refractory are allowed to enroll into the TACo arm regardless of BRAF status.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents",
                    "criterion": "prior treatment with anti-PD-1, anti-PD-L1, or pathway targeting agents",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met: Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose.",
                    "criterion": "prior treatment with anti-CTLA-4",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since first dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "No history of severe immune-related adverse effects from anti-CTLA 4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] Grade 3 and 4)",
                    "criterion": "severe immune-related adverse effects from anti-CTLA-4",
                    "requirements": [
                        {
                            "requirement_type": "history of severe adverse effects (CTCAE Grade 3 or 4)",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who are PD-1 refractory are allowed to enroll into the TACo arm regardless of BRAF status.",
                    "criterion": "PD-1 refractory status",
                    "requirements": [
                        {
                            "requirement_type": "PD-1 refractory",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%) No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)",
            "criterions": [
                {
                    "exact_snippets": "Disease is well controlled at baseline",
                    "criterion": "disease control status at baseline",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "well controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)",
                    "criterion": "topical steroid requirement",
                    "requirements": [
                        {
                            "requirement_type": "potency",
                            "expected_value": "low"
                        },
                        {
                            "requirement_type": "route",
                            "expected_value": "topical"
                        }
                    ]
                },
                {
                    "exact_snippets": "No acute exacerbations of underlying condition within the last 12 months",
                    "criterion": "acute exacerbations of underlying condition",
                    "requirements": [
                        {
                            "requirement_type": "occurrence in last 12 months",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids",
                    "criterion": "requirement for systemic or high potency therapies",
                    "requirements": [
                        {
                            "requirement_type": "requirement for therapies",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "therapies",
                            "expected_value": [
                                "PUVA",
                                "methotrexate",
                                "retinoids",
                                "biologic agents",
                                "oral calcineurin inhibitors",
                                "high potency steroids",
                                "oral steroids"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (Bevacizumab-related exclusion) Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)",
            "criterions": [
                {
                    "exact_snippets": "Evidence of bleeding diathesis",
                    "criterion": "bleeding diathesis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "significant coagulopathy (in the absence of therapeutic anticoagulation)",
                    "criterion": "coagulopathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "context",
                            "expected_value": "in the absence of therapeutic anticoagulation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia",
            "criterions": [
                {
                    "exact_snippets": "Severe infections within 4 weeks prior to cycle 1, day 1",
                    "criterion": "severe infections",
                    "requirements": [
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to cycle 1, day 1"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hospitalization for complications of infection",
                    "criterion": "hospitalization for complications of infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "bacteremia",
                    "criterion": "bacteremia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "severe pneumonia",
                    "criterion": "severe pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (Bevacizumab-related exclusion) Clinically significant (i.e. active) cardiovascular disease, for example cerebrovascular accidents =< 6 months prior to study enrolment, myocardial infarction =< 6 months prior to study enrollment, unstable angina, grade II or greater congestive heart failure, or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant (i.e. active) cardiovascular disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "clinical_significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cerebrovascular accidents =< 6 months prior to study enrolment",
                    "criterion": "cerebrovascular accident",
                    "requirements": [
                        {
                            "requirement_type": "time_since_event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction =< 6 months prior to study enrollment",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time_since_event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "grade II or greater congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "severity_grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment",
                    "criterion": "serious cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "control_by_medication",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "potential_to_interfere_with_protocol_treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis a) Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible. b) Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible. c) Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations; rash must cover less than 10% of body surface area (BSA)",
            "criterions": [
                {
                    "exact_snippets": "History of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis",
                    "criterion": "history of autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible",
                    "criterion": "autoimmune hypothyroidism",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment stability",
                            "expected_value": "stable dose of thyroid replacement hormone"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible",
                    "criterion": "Type 1 diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "controlled"
                        },
                        {
                            "requirement_type": "treatment stability",
                            "expected_value": "stable insulin regimen"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted",
                    "criterion": "eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only",
                    "requirements": [
                        {
                            "requirement_type": "manifestation type",
                            "expected_value": "dermatologic only"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with psoriatic arthritis would be excluded",
                    "criterion": "psoriatic arthritis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations",
                    "criterion": "psoriasis",
                    "requirements": [
                        {
                            "requirement_type": "ophthalmologic exam",
                            "expected_value": "baseline exam to rule out ocular manifestations"
                        }
                    ]
                },
                {
                    "exact_snippets": "rash must cover less than 10% of body surface area (BSA)",
                    "criterion": "rash body surface area coverage",
                    "requirements": [
                        {
                            "requirement_type": "coverage",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "% BSA"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (Bevacizumab-related exclusion) History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month of study enrollment for any tumor type",
            "criterions": [
                {
                    "exact_snippets": "History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month of study enrollment",
                    "criterion": "hemoptysis",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month"
                            }
                        },
                        {
                            "requirement_type": "severity_per_episode",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "teaspoon of bright red blood"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan a) history of radiation pneumonitis in the radiation field (fibrosis) is permitted",
            "criterions": [
                {
                    "exact_snippets": "History of idiopathic pulmonary fibrosis",
                    "criterion": "idiopathic pulmonary fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pneumonitis (including drug induced)",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.)",
                    "criterion": "organizing pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of active pneumonitis on screening chest computed tomography (CT) scan",
                    "criterion": "active pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "presence_on_CT_scan",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inability to swallow medications",
            "criterions": [
                {
                    "exact_snippets": "Inability to swallow medications",
                    "criterion": "ability to swallow medications",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of ongoing serous retinopathy or RVO at screening",
            "criterions": [
                {
                    "exact_snippets": "Evidence of ongoing serous retinopathy ... at screening",
                    "criterion": "serous retinopathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "Evidence of ongoing ... RVO at screening",
                    "criterion": "retinal vein occlusion (RVO)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (Bevacizumab-related exclusion) Current or recent (within 10 days of study enrolment) use of aspirin (> 325 mg/day), clopidogrel (> 75 mg/day), or current or recent (within 10 days prior to first dose of bevacizumab) use of therapeutic oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes Note: The use of full-dose oral or parenteral anticoagulants is NOT permitted for at least two weeks at the time of study enrollment. Prophylactic use of anticoagulants is NOT allowed",
            "criterions": [
                {
                    "exact_snippets": "Current or recent (within 10 days of study enrolment) use of aspirin (> 325 mg/day)",
                    "criterion": "aspirin use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 10,
                                        "unit": "days"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 325,
                                "unit": "mg/day"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Current or recent (within 10 days of study enrolment) use of ... clopidogrel (> 75 mg/day)",
                    "criterion": "clopidogrel use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 10,
                                        "unit": "days"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 75,
                                "unit": "mg/day"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "current or recent (within 10 days prior to first dose of bevacizumab) use of therapeutic oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes",
                    "criterion": "therapeutic oral or parenteral anticoagulant or thrombolytic agent use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 10,
                                        "unit": "days"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": "therapeutic"
                        }
                    ]
                },
                {
                    "exact_snippets": "The use of full-dose oral or parenteral anticoagulants is NOT permitted for at least two weeks at the time of study enrollment.",
                    "criterion": "full-dose oral or parenteral anticoagulant use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "dosage",
                            "expected_value": "full-dose"
                        }
                    ]
                },
                {
                    "exact_snippets": "Prophylactic use of anticoagulants is NOT allowed",
                    "criterion": "prophylactic anticoagulant use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study a) Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study",
            "criterions": [
                {
                    "exact_snippets": "Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1",
                    "criterion": "live, attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration before cycle 1, day 1",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation that such a live, attenuated vaccine will be required during the study",
                    "criterion": "anticipated need for live, attenuated vaccine",
                    "requirements": [
                        {
                            "requirement_type": "anticipated administration during study",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to cycle 1, day 1 or at any time during the study",
                    "criterion": "live, attenuated influenza vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration before cycle 1, day 1",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "administration during study",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any approved anticancer therapy, including chemotherapy and hormonal therapy within 3 weeks prior to initiation of study treatment; however, the following are allowed: a) Hormone-replacement therapy or oral contraceptives b) Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)",
            "criterions": [
                {
                    "exact_snippets": "Any approved anticancer therapy, including chemotherapy and hormonal therapy within 3 weeks prior to initiation of study treatment",
                    "criterion": "approved anticancer therapy (including chemotherapy and hormonal therapy)",
                    "requirements": [
                        {
                            "requirement_type": "absence within time window",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "weeks prior to initiation of study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Hormone-replacement therapy or oral contraceptives ... are allowed",
                    "criterion": "hormone-replacement therapy or oral contraceptives",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)",
                    "criterion": "herbal therapy",
                    "requirements": [
                        {
                            "requirement_type": "absence within time window",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "week prior to cycle 1, day 1"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1",
                    "criterion": "herbal therapy intended as anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation time before treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week prior to cycle 1, day 1"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Known hypersensitivity to any component of bevacizumab, atezolizumab, or cobimetinib",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to any component of bevacizumab",
                    "criterion": "hypersensitivity to bevacizumab components",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity to any component of atezolizumab",
                    "criterion": "hypersensitivity to atezolizumab components",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity to any component of ... cobimetinib",
                    "criterion": "hypersensitivity to cobimetinib components",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Malabsorption condition that would alter the absorption of rally administered medications",
            "criterions": [
                {
                    "exact_snippets": "Malabsorption condition that would alter the absorption of orally administered medications",
                    "criterion": "malabsorption condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "effect on absorption of orally administered medications",
                            "expected_value": "would alter"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}